Seminars in Oncology Nursing
Volume 22 , Pages 5-9 , February 2006

EGFR as a Target: Rationale for Therapy

  • Debra Wujcik

      Affiliations

    • Corresponding Author InformationAddress correspondence to Debra Wujcik, RN, MSN, AOCN®, Clinical Trials Office, 9th Floor, 1818 Albion St, Nashville, TN 37208

References 

  1. Aaronson SA . Growth factors and cancer . Science . 1991;254:1146–1153
  2. Herbst RS , Shin DM . Monoclonal antibodies to target epidermal growth factor receptor-positive tumors (A new paradigm for cancer therapy) . Cancer . 2002;94:1593–1611
  3. Yarden Y , Sliwkowski MX . Untangling the ErbB signalling network . Nat Rev Mol Cell Biol . 2001;2:127–137
  4. Mendelsohn J . The epidermal growth factor as a target for cancer therapy . Endo Rel Cancer . 2001;8:3–9
  5. Baselga J . Why the epidermal growth factor receptor? The rationale for cancer therapy . Oncologist . 2002;7(suppl 4):2–8
  6. Schlessinger J . Cell signaling by receptor tyrosine kinases . Cell . 2000;103:211–225
  7. Moyer JD , Barbacci EG , Iwata KK , et al.   Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase . Cancer Res . 1997;57:4838–4848
  8. Arteaga CL . The epidermal growth factor receptor (from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia) . J Clin Oncol . 2001;19(suppl):32s–40s
  9. Ennis BW , Lippman ME , Dickson RB . The EGF receptor system as a target for antitumor therapy . Cancer Invest . 1991;9:553–562
  10. Ross JS , Fletcher JA . The HER-2/neu oncogene in breast cancer (Prognostic factor, predictive factor, and target for therapy) . Stem Cells . 1998;16:413–428
  11. Brabender J , Danenberg KD , Metzger R , et al.   Epidermal growth factor receptor and HER2-neu mRNA expression in non–small cell lung cancer is correlated with survival . Clin Cancer Res . 2001;7:1850–1855
  12. ERBITUX [package insert]. New York, NY. ImClone Systems Incorporated, and Princeton, NJ: Bristol-Myers Squibb Company; 2004.
  13. Harris M . Monoclonal antibodies as therapeutic agents for cancer . Lancet Oncol . 2004;5:292–302
  14. Stocchi L , Nelson H . Diagnostic and therapeutic applications of monoclonal antibodies in colorectal cancer . Dis Colon Rectum . 1998;41:232–250
  15. LoBuglio AF , Wheeler RH , Trang J , et al.   Mouse/human chimeric monoclonal antibody in man (kinetics and immune response) . Proc Natl Acad Sci U S A . 1989;86:4220–4224
  16. Shitara K , Kuwana Y , Nakamura K , et al.   A mouse/human chimeric anti-(ganglioside GD3) antibody with enhanced antitumor activities . Cancer Immunol Immunother . 1993;36:373–380
  17. Gill GN , Kawamoto T , Cochet C , et al.   Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine kinase activity . J Biol Chem . 1984;259:7755–7760
  18. Sato JD , Kawamoto T , Le AD , et al.   Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors . Mol Biol Med . 1983;1:511–529
  19. Prewett MC , Hooper AT , Bassi R , et al.   Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts . Clin Cancer Res . 2002;8:994–1003
  20. Saltz LB , Meropol NJ , Loehrer PJ , et al.   Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor . J Clin Oncol . 2004;22:1201–1208
  21. Cunningham D , Humblet Y , Siena S , et al.   Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer . N Engl J Med . 2004;351:337–345
  22. Bonner JA , Giralt J , Harari PM , et al.   Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of the head and neck (A phase III study of high dose radiation therapy with or without cetuximab) . [abstract] J Clin Oncol . 2004;22(suppl):5507
  23. Herbst RS . Review of epidermal growth factor receptor biology . Int J Radiat Oncol Biol Phys . 2004;59(suppl):21–26
  24. Castillo L , Etienne-Grimaldi MC , Fischel JL , et al.   Pharmacological background of EGFR targeting . Ann Oncol . 2004;15:1007–1012
  25. Fukuoka M , Yano S , Giaccone G , et al.   Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non–small-cell lung cancer . J Clin Oncol . 2003;21:2237–2246
  26. Kris MG , Natale RB , Herbst RS , et al.   Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non–small cell lung cancer (A randomized trial) . JAMA . 2003;290:2149–2158
  27. Giaccone G , Herbst RS , Manegold C , et al.   Gefitinib in combination with gemcitabine and cisplatin in advanced non–small-cell lung cancer (A phase III trial—INTACT 1) . J Clin Oncol . 2004;22:777–784
  28. Shepherd FA , Pereira J , Ciuleanu T , et al.   A randomized placebo-controlled trial of erlotinib in patients with advanced non–small cell lung cancer (NSCLC) following failure of 1st line and 2nd line chemotherapy (A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial) . [abstract] J Clin Oncol . 2004;22(suppl):7022
  29. Soulieres D , Senzer NN , Vokes EE , et al.   Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck . J Clin Oncol . 2004;22:77–85
  30. Moore MJ , Goldstein D , Hamm J , et al.   Erlotinib improves survival when added to gemcitabine in patients with advanced pancreatic cancer (A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]) . [abstract] J Clin Oncol . 2005;23(suppl):1
  31. Iressa tablets [package insert] . Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2004;
  32. Tarceva tablets [package insert]. South San Francisco, CA. Genentech, Inc, and Melville, NY: OSI Pharmaceuticals Inc; 2004.
  33. Baselga J . Targeting the epidermal growth factor receptor (A clinical reality) . J Clin Oncol . 2001;15(suppl):41s–44s
  34. Herbst RS , Shin DM . Monoclonal antibodies to target epidermal growth factor receptor-positive tumors (A new paradigm for cancer therapy) . Cancer . 2002;94:1593–1611

 Supported in part by a grant from Bristol-Myers Squibb Company.

PII: S0749-2081(06)00033-7

doi: 10.1016/j.soncn.2006.01.010

Seminars in Oncology Nursing
Volume 22 , Pages 5-9 , February 2006

Article Tools

* Image Usage & Resolution